Lexeo Therapeutics, Inc.
LXEO
$4.87
$0.214.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.10M | -32.66M | -25.92M | -29.49M | -21.24M |
| Total Depreciation and Amortization | 510.00K | 501.00K | 521.00K | 509.00K | 496.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -285.00K | 3.71M | 3.48M | 3.79M | 2.85M |
| Change in Net Operating Assets | -1.34M | 6.73M | -6.41M | 7.38M | -2.26M |
| Cash from Operations | -27.22M | -21.72M | -28.33M | -17.81M | -20.15M |
| Capital Expenditure | -108.00K | -- | 0.00 | -83.00K | -213.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.07M | 15.60M | -93.58M | 0.00 | -5.00K |
| Cash from Investing | -39.17M | 15.60M | -93.58M | -83.00K | -218.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -122.00K | -159.00K | -116.00K | -111.00K | -74.00K |
| Issuance of Common Stock | 80.00M | 170.00K | 6.31M | 39.00K | 6.67M |
| Repurchase of Common Stock | -- | -- | -4.00K | 0.00 | -13.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.92M | -- | -6.29M | -- | -6.29M |
| Cash from Financing | 72.96M | 11.00K | -97.00K | -72.00K | 291.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.57M | -6.11M | -122.01M | -17.96M | -20.08M |